Table 1.

Baseline demographic and clinical characteristics of study participants

Characteristics	Cilostazol (n = 18)	Control (n = 18)	p
Mean age (years)	79.00 ± 6.26	78.06 ± 6.09	0.65
Female patients, n (%)	13 (72.22)	15 (83.33)	0.69*
Education (years)	5.56 ± 5.62	4.72 ± 4.61	0.76†
MMSE	15.11 ± 3.61	15.44 ± 3.96	0.79
ADAS-cog	29.28 ± 8.79	27.78 ± 7.89	0.59
ADCS-ADL	50.17 ± 11.61	53.56 ± 14.86	0.45
CDR, n (%)			0.37*
0.5	4 (22.22)	1 (5.56)
1	12 (66.67)	16 (88.89)
2	2 (11.11)	1 (5.56)
Fazekas scale, n (%)			0.87*
1	13 (72.22)	11 (61.11)
2	3 (16.67)	5 (27.78)
3	2 (11.11)	2 (11.11)

Data are expressed as mean ± SD with the exception of the number of female patients, CDR, and Fazekas scale. Independent t tests were used for comparisons unless otherwise indicated

MMSE = Mini-Mental State Exam; ADAS-cog = cognitive portion of the Alzheimer’s Disease Assessment Scale; ADCS-ADL = the Alzheimer’s Disease Cooperative Study-Activities of Daily Living Inventory; CDR = baseline Clinical Dementia Rating Scale

*χ² test

^†Mann–Whitney U test